Protective potential of high-intensity interval training on cardiac structure and function after COVID-19: protocol and statistical analysis plan for an investigator-blinded randomised controlled trial
Lars Køber,
Mathias Ried-Larsen,
Bente Klarlund Pedersen,
Niels Vejlstrup,
Frederik Foged,
Iben Elmerdahl Rasmussen,
Josephine Bjørn Budde,
Rasmus Syberg Rasmussen,
Villads Rasmussen,
Mark Lyngbæk,
Simon Jønck,
Rikke Krogh-Madsen,
Birgitte Lindegaard,
Regitse Højgaard Christensen,
Peter Godsk Jørgensen,
Morten Asp Vonsild Lund,
Ronan M G Berg
Affiliations
Lars Køber
Department of Cardiology, University Hospital Copenhagen - Rigshospitalet, Copenhagen, Denmark
Mathias Ried-Larsen
Centre for Physical Activity Research, Rigshospitalet, Copenhagen, Region Hovedstaden, Denmark
Bente Klarlund Pedersen
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Niels Vejlstrup
Department of Cardiology, University Hospital Copenhagen - Rigshospitalet, Copenhagen, Denmark
Frederik Foged
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Iben Elmerdahl Rasmussen
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Josephine Bjørn Budde
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Rasmus Syberg Rasmussen
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Villads Rasmussen
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Mark Lyngbæk
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Simon Jønck
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Rikke Krogh-Madsen
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Birgitte Lindegaard
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Regitse Højgaard Christensen
Department of Cardiology, University Hospital Copenhagen - Rigshospitalet, Copenhagen, Denmark
Peter Godsk Jørgensen
Department of Cardiology, University Hospital Copenhagen - Rigshospitalet, Copenhagen, Denmark
Morten Asp Vonsild Lund
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Ronan M G Berg
Centre for Physical Activity Research (CFAS), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Introduction COVID-19 is associated with a marked systemic inflammatory response with concomitant cardiac injury and remodelling, but it is currently unknown whether the latter is reversible. Given that high-intensity interval training (HIIT) is a powerful stimulus to improve cardiorespiratory fitness while also eliciting marked anti-inflammatory effects, it may be an important countermeasure of reducing cardiopulmonary morbidity following COVID-19.Methods and analysis 40 COVID-19 survivors who have been discharged from hospital will be included in this investigator-blinded randomised study with a 12-week HIIT intervention. Patients will be 1:1 block-randomised by sex to either a supervised HIIT exercise group or standard care (control group). The main hypothesis is that a 12-week HIIT scheme is a safe way to improve loss of cardiac mass and associated cardiorespiratory fitness, despite hypothesised limited HIIT-induced changes in conventional lung function indices per se. Ultimately, we hypothesise that the HIIT scheme will reduce post-COVID-19 symptoms and improve quality of life.Ethics and dissemination This study is approved by the Scientific Ethical Committee at the Capital Region of Denmark (H-20033733, including amendments 75068 and 75799) and registered at ClinicalTrials.gov (NCT04647734, pre-results). The findings will be published in a peer-reviewed journal, including cases of positive, negative and inconclusive results.Trial registration number NCT04549337.